Methemoglobinemia and hemolytic anemia after rasburicase administration in a child with leukemia

Case We report a case of simultaneous methemoglobinemia and hemolytic anemia, probably related to the use of rasburicase, in a child starting treatment for acute lymphoblastic leukemia (ALL). In addition, the patient developed symptoms of pancreatitis. All complications resolved after 3 days of supp...

Full description

Saved in:
Bibliographic Details
Published in:International journal of clinical pharmacy 2011-02, Vol.33 (1), p.58-60
Main Authors: Bauters, T., Mondelaers, V., Robays, H., De Wilde, H., Benoit, Y., De Moerloose, B.
Format: Article
Language:English
Subjects:
Anemia
Anemia, Hemolytic - chemically induced
Case Report
Child
Humans
Internal Medicine
Leukemia
Male
Medicine
Medicine & Public Health
Methemoglobinemia - chemically induced
Oncology
Pancreatitis - complications
Pancreatitis - therapy
Pharmacology
Pharmacy
Precursor Cell Lymphoblastic Leukemia-Lymphoma - complications
Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy
Side effects
Tumor Lysis Syndrome - prevention & control
Tumors
Urate Oxidase - adverse effects
Urate Oxidase - therapeutic use
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Case We report a case of simultaneous methemoglobinemia and hemolytic anemia, probably related to the use of rasburicase, in a child starting treatment for acute lymphoblastic leukemia (ALL). In addition, the patient developed symptoms of pancreatitis. All complications resolved after 3 days of supportive therapy. Conclusion Although usually well tolerated in pediatrics, physicians prescribing rasburicase should be aware of these possible life-threatening adverse reactions.
ISSN:2210-7703
2210-7711
DOI:10.1007/s11096-011-9484-3